BR112020026014A8 - Derivado de lactama condensado - Google Patents

Derivado de lactama condensado

Info

Publication number
BR112020026014A8
BR112020026014A8 BR112020026014A BR112020026014A BR112020026014A8 BR 112020026014 A8 BR112020026014 A8 BR 112020026014A8 BR 112020026014 A BR112020026014 A BR 112020026014A BR 112020026014 A BR112020026014 A BR 112020026014A BR 112020026014 A8 BR112020026014 A8 BR 112020026014A8
Authority
BR
Brazil
Prior art keywords
lactam derivative
condensed
condensed lactam
derivative
medicament
Prior art date
Application number
BR112020026014A
Other languages
English (en)
Other versions
BR112020026014A2 (pt
Inventor
Yoshinaga Hidefumi
Ikuma Yohei
Ikeda Junya
Adachi Satoshi
Mitsunuma Harunobu
Aihara Yoshinori
Besnard Jeremy
Simon Bell Andrew
Original Assignee
Sumitomo Dainippon Pharma Co Ltd
Sumitomo Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Dainippon Pharma Co Ltd, Sumitomo Pharma Co Ltd filed Critical Sumitomo Dainippon Pharma Co Ltd
Publication of BR112020026014A2 publication Critical patent/BR112020026014A2/pt
Publication of BR112020026014A8 publication Critical patent/BR112020026014A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Abstract

A presente invenção se refere a um medicamento para o tratamento de doenças neuropsiquiátricas que compreende um composto de Fórmula (1): , ou um sal farmaceuticamente aceitável do mesmo, como um ingrediente ativo.
BR112020026014A 2018-07-23 2019-07-22 Derivado de lactama condensado BR112020026014A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018-138029 2018-07-23
JP2018138029 2018-07-23
PCT/JP2019/028577 WO2020022237A1 (ja) 2018-07-23 2019-07-22 縮環ラクタム誘導体

Publications (2)

Publication Number Publication Date
BR112020026014A2 BR112020026014A2 (pt) 2021-03-23
BR112020026014A8 true BR112020026014A8 (pt) 2022-12-06

Family

ID=69180566

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020026014A BR112020026014A8 (pt) 2018-07-23 2019-07-22 Derivado de lactama condensado

Country Status (14)

Country Link
US (2) US11466007B2 (pt)
EP (1) EP3828182A4 (pt)
JP (2) JP7387605B2 (pt)
KR (1) KR20210035247A (pt)
CN (1) CN112424195A (pt)
AU (1) AU2019309130B2 (pt)
BR (1) BR112020026014A8 (pt)
CA (1) CA3105428A1 (pt)
EA (1) EA202190316A1 (pt)
MX (1) MX2021000942A (pt)
PH (1) PH12021550146A1 (pt)
SG (1) SG11202100011VA (pt)
TW (1) TW202012401A (pt)
WO (1) WO2020022237A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111961047A (zh) * 2020-08-19 2020-11-20 南通大学 一种6-乙氧基-3,4-二氢-2,7-萘啶-1（2h）-酮及其合成方法
WO2024042480A1 (en) * 2022-08-26 2024-02-29 Suven Life Sciences Limited Heteroaromatic compounds for the treatment of neurological disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0465254B1 (en) 1990-07-06 1996-11-13 Yoshitomi Pharmaceutical Industries, Ltd. Fused thiophene compounds and uses thereof
JPH0543582A (ja) * 1990-07-06 1993-02-23 Yoshitomi Pharmaceut Ind Ltd チオフエン縮合化合物およびその用途
US5114936A (en) 1990-08-23 1992-05-19 Hoechst-Roussel Pharmaceuticals Incorporated 6,7-dihydro-3-phenyl-1,2-benzisoxazol-4(5h)-ones and -ols, compositions and pharmaceutical use
US5532240A (en) * 1991-12-26 1996-07-02 Yoshitomi Pharmaceutical Industries, Ltd. Condensed thiophene compound and pharmaceutical use thereof
CA2104371A1 (en) * 1991-12-26 1993-06-27 Tohru Nakao Condensed thiophene compound and pharmaceutical use thereof
EP0807632B1 (en) 1995-12-01 2002-04-17 Suntory Limited Pyrroloazepine derivatives

Also Published As

Publication number Publication date
KR20210035247A (ko) 2021-03-31
US20200255432A1 (en) 2020-08-13
TW202012401A (zh) 2020-04-01
US20230008875A1 (en) 2023-01-12
JPWO2020022237A1 (ja) 2021-08-02
SG11202100011VA (en) 2021-02-25
BR112020026014A2 (pt) 2021-03-23
JP2024020396A (ja) 2024-02-14
AU2019309130A1 (en) 2021-02-11
MX2021000942A (es) 2021-03-31
WO2020022237A1 (ja) 2020-01-30
EA202190316A1 (ru) 2021-05-20
EP3828182A4 (en) 2022-04-20
JP7387605B2 (ja) 2023-11-28
CN112424195A (zh) 2021-02-26
EP3828182A1 (en) 2021-06-02
CA3105428A1 (en) 2020-01-30
US11466007B2 (en) 2022-10-11
AU2019309130B2 (en) 2024-04-18
PH12021550146A1 (en) 2021-09-13

Similar Documents

Publication Publication Date Title
CL2019002204A1 (es) Compuestos inhibidores del vih.
DOP2019000187A (es) Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo
EA201891703A1 (ru) Соединения бензопиразола и их аналоги
CL2020000886A1 (es) Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih.
TN2015000391A1 (en) Compounds and compositions for the treatment of parasitic diseases
DOP2024000039A (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
PH12020552017A1 (en) 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof
EA202091604A1 (ru) Ингибирование ионного канала a1 с транзиторным рецепторным потенциалом
MX2020013297A (es) Compuestos para el tratamiento o la prevencion de enfermedades hepaticas.
BR112016026552A8 (pt) derivados de carboxamida, seus usos, composição farmacêutica, e combinação
MX2022000945A (es) Composicion para incrementar la expresion de pgc-1alfa.
BR112021011325A2 (pt) Derivados de rapamicina
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
BR112020026014A8 (pt) Derivado de lactama condensado
PH12020551297A1 (en) Compounds having s1p5 receptor agonistic activity
PH12019502652A1 (en) 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
CO2022008616A2 (es) Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma
PE20190452A1 (es) Derivado de triazolopirazinona util como un inhibidor de pde1 humana
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
BR112021002126A2 (pt) Composição para dispensação de vírus, e, método para preparação de uma composição para dispensação de vírus.
CO2020001375A2 (es) Derivado de adamantilmetilamina y uso del mismo como producto farmacéutico
EA201992577A1 (ru) 5,6-конденсированные бициклические соединения и композиции для лечения паразитарных заболеваний
PH12019501027A1 (en) Therapeutic drug or prophylactic drug for diabetic nephropathy
EA201991910A1 (ru) Трициклическое соединение и пути его применения
PH12017500106A1 (en) Prophylactic or therapeutic agent for a posterior ocular disease

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: SUMITOMO PHARMA CO., LTD. (JP)

B25G Requested change of headquarter approved

Owner name: SUMITOMO PHARMA CO., LTD. (JP)

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]